Significant itch reduction in CUPID-A and CUPID-C at Week 24
CUPID-A (12+ YEARS)
ISS7 - WEEKLY ITCH
(Week 12, secondary endpoint; Week 24, primary endpoint)1,2
Mean ISS7 at baseline—DUPIXENT: 16.25 (SD, 3.90); placebo: 15.74 (SD, 4.11).2
CUPID-C (12+ YEARS)
vs 33% reductiona in ISS7 at Week 24
(DUPIXENT: -8.50 vs placebo: -6.13; P=0.0270, primary endpoint)1,2
- 37% vs 28% reductiona in ISS7 at Week 12 (DUPIXENT: -6.98 vs placebo: -5.34, secondary endpoint; not significant)2
- Mean ISS7 at baseline: DUPIXENT (n=73): 15.18 (SD, 3.59); placebo (n=75): 14.96 (SD, 3.94)2
Definitive conclusions cannot be made for Week 12 as the analysis was not multiplicity controlled.
Use of DUPIXENT for the CSU indication in patients aged 2-11 years is supported by evidence from two studies of DUPIXENT in CSU patients 12+ years of age.1
aLSM change from baseline.
CUPID-A AND CUPID-C POOLED ANALYSIS (12+ YEARS)
In a post hoc pooled analysis of CUPID-A and CUPID-C, improvement in ISS7:
Was observed as early as Week 3
- 32% vs 23% reduction from baseline, respectively2
Mean ISS7 at baseline—DUPIXENT: 15.7 (SD, 3.77); placebo: 15.33 (SD, 4.02).2
Definitive conclusions cannot be made as this was a post hoc analysis which was not multiplicity controlled.
Improvement in ISS7 and UAS7 at Week 24 with DUPIXENT Across a Broad Range of CSU Patient Types (12+ Years)
in a post-hoc pooled analysis of CUPID A and CUPID C,
regardless of1,2:
- IgE levels
- BMI
- Angioedema
Real CSU patient being treated with DUPIXENT.
Individual results may vary.
Itch severity score (ISS) is a patient-reported assessment rated on a scale of 0 (none), 1 (mild itch), 2 (moderate itch), and 3 (intense itch). ISS7 is the sum of the preceding 7 days’ itch scores, for a total ISS7 range of 0 to 21.2
See which patients with CSU may be appropriate for DUPIXENT
BMI, body mass index; CSU, chronic spontaneous urticaria; ISS7, itch severity score over 7 days; LSM, least squares mean; SD, standard deviation; UAS7, urticaria activity score over 7 days.